Literature DB >> 19290525

Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.

Isabel Möller, Sabine Blum, Norbert Gattermann, Rainer Haas, Kerstin Habersang, Ulrich Germing, Andrea Kuendgen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19290525     DOI： 10.1007/s00277-009-0730-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

Review 1.  Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.

Authors:  Jean-Noël Bastie; Romain Aucagne; Nathalie Droin; Eric Solary; Laurent Delva
Journal:  Cell Mol Life Sci       Date:  2012-03-14       Impact factor: 9.261

2.  A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.

Authors:  Kai-Xun Hu; Qi-Yun Sun; Mei Guo; Jun-Xiao Qiao; Chang-Lin Yu; Jian-Hui Qiao; Zheng Dong; Wan-Jun Sun; Hong-Li Zuo; Ya-Jing Huang; Bo Cai; Hui-Sheng Ai
Journal:  Stem Cells Transl Med       Date:  2016-02-02       Impact factor: 6.940

3.  A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.

Authors:  Ning Ding; Xiao-Xing Cui; Zhi Gao; Huarong Huang; Xingchuan Wei; Zhiyun Du; Yong Lin; Weichung Joe Shih; Arnold B Rabson; Allan H Conney; Chunhong Hu; Xi Zheng
Journal:  Int J Oncol       Date:  2014-03-19       Impact factor: 5.650
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.